Marty Makary

So I want to give a flip side to this.

The right to try law gives patients access to drugs that when they're in a certain condition, they can access the drug before it's gone through full approvals.

The right to try law gives patients access to drugs that when they're in a certain condition, they can access the drug before it's gone through full approvals.

What's the current state of right to try?

What's the current state of right to try?

Where do you view that going?

Where do you view that going?

And does the threshold for right to try change over time, giving patients and their doctors more rights and more access sooner?

And does the threshold for right to try change over time, giving patients and their doctors more rights and more access sooner?

Or does the FDA still have to hold firm?

Or does the FDA still have to hold firm?

How do you think about that over time?

How do you think about that over time?

So let me just understand that one.

So let me just understand that one.

I've spent a little time in this space.

I've spent a little time in this space.

Does this mean that I will not need to go through a GMP or good manufacturing practice facility to bring those therapeutics to a broader set of patients?

Does this mean that I will not need to go through a GMP or good manufacturing practice facility to bring those therapeutics to a broader set of patients?

And does it also mean that once I've got a system that works, I can use it for different indications and maybe help understand a little bit about where this goes?